Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,843 across all filing types
Latest filing 2014-04-08 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
2013年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2013 Annual General Meeting (AGM) of 普洛药业股份有限公司. It details the legality and validity of the AGM's convening, attendance, agenda, and voting procedures. The document references the 2013 Annual Report and other reports as agenda items but does not contain the reports themselves. The document length is 4380 characters, which is relatively short and consistent with a legal opinion or meeting-related document rather than a full report. The content focuses on the AGM process and legal compliance, not on financial results or management discussion. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the meeting.
2014-04-08 Chinese
第六届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution from the first meeting of the sixth supervisory board of the company, including the election of the supervisory board chairman. It contains no financial data, no report or presentation, and no regulatory certification. It is a formal announcement related to board/management information, specifically about the supervisory board leadership change. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2014-04-08 Chinese
2013年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2013 Annual General Meeting (AGM) of 普洛药业股份有限公司, held on April 8, 2014. It includes voting results on various proposals such as approval of the 2013 annual report, election of directors and supervisors, appointment of auditors, amendments to the company charter, and approval of a non-public issuance of A shares. The document is focused on the outcomes of shareholder votes and meeting proceedings rather than the full annual report or financial statements themselves. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a Management Report or Earnings Release. The content aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting results from the AGM. The document length (8276 characters) and detailed voting data support this classification rather than a brief announcement or a report publication notice.
2014-04-08 Chinese
限售股上市流通的提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a formal announcement from a company regarding the lifting of restrictions on certain shares, allowing them to be freely traded on the stock exchange. It details the number of shares becoming tradable, the shareholders involved, the dates of restriction lifting, and compliance with relevant securities laws and regulations. There is no financial statement, earnings data, or management discussion. The document is not a report but an official notice about share circulation changes. This fits the category of Share Issue/Capital Change announcements, specifically about restricted shares becoming tradable.
2014-04-07 Chinese
关于召开2013年度股东大会的提示性公告
AGM Information Classification · 95% confidence The document is a detailed announcement about the convening of the 2013 Annual General Meeting (AGM) of 普洛药业股份有限公司 (Puloyao Pharmaceutical Co., Ltd.). It includes the meeting date, voting procedures (both onsite and online), agenda items for shareholder approval, including the 2013 annual report, board and supervisory reports, profit distribution, election of directors and supervisors, appointment of auditors, amendments to the company charter, and non-public stock issuance plans. It also contains instructions for shareholder registration, proxy voting, and detailed voting codes for each agenda item. The document is a notice or announcement related to the AGM, not the actual AGM materials or reports themselves. It does not contain the full annual report or financial statements but references them as agenda items to be discussed and voted on at the meeting. The document length is 8698 characters, which is substantial but consistent with a comprehensive AGM notice. Therefore, the document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices about the AGM itself.
2014-03-31 Chinese
董事会关于近日媒体传闻的说明
Regulatory Filings Classification · 95% confidence The document is a public announcement from the board of directors of 普洛药业股份有限公司 addressing recent media rumors about the company's supply chain and product quality. It clarifies misinformation, confirms compliance with regulatory standards, and reassures investors about the company's disclosure practices. The document does not contain financial statements, audit results, or detailed financial data. It is a regulatory announcement aimed at clarifying information and maintaining transparency with investors. Given its nature as a public clarification and assurance statement without financial data or report content, it fits best under Regulatory Filings (RNS). The document length is short (933 characters), and it is not an announcement of a report publication but a direct statement from the board.
2014-03-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.